Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 15/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 15/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 15/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 15/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 15/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 15/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.34 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.34 |
| ▸ | LDLR | P01130 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14257623 | 0.78 | RAB9A (0.44) | — | |
| SCHEMBL2253468 | 0.78 | RAB9A (0.44) | — | |
| SCHEMBL2253462 | 0.78 | RAB9A (0.44) | — | |
| SCHEMBL14257490 | 0.77 | KMT2A (0.37) | — | |
| SCHEMBL929052 | 0.74 | NPC1 (0.48) | — | |
| SCHEMBL929051 | 0.74 | NPC1 (0.48) | — | |
| SCHEMBL4987913 | 0.72 | NPY2R (0.44) | — | |
| SCHEMBL4987906 | 0.72 | NPY2R (0.44) | — | |
| SCHEMBL14036792 | 0.72 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30411025 | 0.72 | NOTUM (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |